Market Overview:
The global communicable diseases treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of communicable diseases, rising awareness about available treatments, and growing demand for novel therapies. The global communicable diseases treatment market is segmented on the basis of type into HIV, influenza, tuberculosis (TB), malaria, hepatitis, and HPV. The HIV segment is expected to account for the largest share of the market in 2018 owing to high prevalence of the disease across regions. However, HPV is projected to grow at a highest CAGR during the forecast period due its increasing incidence rates globally. On the basis of application, hospitals are expected to account for majority share in 2018 followed by clinics and other applications such as research institutes and home care settings. Hospitals are anticipated witness highest growth during forecast period due rising number patients suffering from chronic conditions that require hospitalization for treatment such as cancer or heart-related problems etcetera .
Product Definition:
A communicable disease is a disease that is easily spread from one person to another. Communicable diseases are often caused by viruses or bacteria. Treatment for communicable diseases varies, depending on the specific illness. However, many common treatments include antibiotics or antiviral medications. The importance of communicable diseases treatment lies in the fact that these illnesses can often be deadly if not treated properly. In addition, proper treatment can help to prevent the spread of these diseases to other people.
HIV:
HIV stands for Human Immunodeficiency Virus. HIV is the virus that attacks the immune system of a human being and makes them susceptible to various diseases, such as Acquired Immunodeficiency Syndrome (AIDS). The disease progression leads to different stages such as primary infection, acute infection and late stage of AIDS. According to UNAIDS, in 2016 around 35 million people were living with HIV across the globe.
Influenza:
Influenza is an infectious disease of the upper respiratory system caused by the influenza virus. The flu is commonly characterized by fever, cough, sore throat, headache and muscle ache. Influenza can affect all ages but generally people over the age of 50 years are more prone to it.
Application Insights:
The other application segment includes home healthcare, self-care, and community care. The global communicable diseases treatment market by application is dominated by the hospital segment owing to the high volume of patients with various conditions that require medical attention. According to WHO, an estimated 9 million people died from CVDs in 2017 globally which accounts for around 31% of all deaths caused by infectious diseases. Thus, a large number of patients suffering from chronic conditions such as cancer and diabetes are registered in hospitals which requires a large amount of diagnostic tests and medicines thus driving the demand for diagnostics tests & medicines used for treating these diseases at affordable costs thereby contributing to overall market growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-developed healthcare infrastructure, high awareness levels coupled with the adoption of advanced technologies and products are some factors responsible for its large share. Moreover, government initiatives such as PEPFAR that provide free medication to patients suffering from HIV/AIDS is expected to boost treatment demand over the forecast period.
Asia Pacific is estimated to be the fastest-growing region during the forecast period owing to rising disposable income and growing patient awareness regarding communicable diseases control programs in this region. Furthermore, increasing investments by governments and non-government organizations (NGOs) for improving healthcare facilities are anticipated to fuel growth over next eight years.
Growth Factors:
- Increasing incidence of communicable diseases: The incidence of communicable diseases is increasing at a rapid pace across the globe. This is primarily owing to the changing lifestyle and environmental conditions. This, in turn, is propelling the demand for effective treatment options for communicable diseases.
- Growing awareness about communicable diseases: There has been a significant rise in the awareness levels about various types of communicable diseases in recent years. People are now more aware about how to prevent these infections and also seek timely treatment options when infected. This is boosting the demand for Communicable Diseases Treatment market globally.
- Rising R&D expenditure by key players: Key players operating in this market are investing heavily in R&D activities to develop novel and effective treatment options for various types of communicable diseases. This is helping them stay ahead of competition and gain a larger share in this lucrative market space.
Scope Of The Report
Report Attributes
Report Details
Report Title
Communicable Diseases Treatment Market Research Report
By Type
HIV, Influenza, TB, Malaria, Hepatitis, HPV
By Application
Hospital, Clinic, Other
By Companies
Novartis, Gilead, GSK, Janssen Pharmaceutical, Roche, BioCryst Pharmaceuticals, Merck, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Communicable Diseases Treatment Market Report Segments:
The global Communicable Diseases Treatment market is segmented on the basis of:
Types
HIV, Influenza, TB, Malaria, Hepatitis, HPV
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Gilead
- GSK
- Janssen Pharmaceutical
- Roche
- BioCryst Pharmaceuticals
- Merck
- Boehringer Ingelheim
Highlights of The Communicable Diseases Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HIV
- Influenza
- TB
- Malaria
- Hepatitis
- HPV
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Communicable Diseases Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Communicable diseases treatment is the process of preventing, diagnosing and treating infections caused by bacteria, viruses or other microorganisms. Treatment may involve antibiotics to kill the infection or antiviral drugs to prevent it from spreading.
Some of the key players operating in the communicable diseases treatment market are Novartis, Gilead, GSK, Janssen Pharmaceutical, Roche, BioCryst Pharmaceuticals, Merck, Boehringer Ingelheim.
The communicable diseases treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Communicable Diseases Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Communicable Diseases Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Communicable Diseases Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Communicable Diseases Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Communicable Diseases Treatment Market Size & Forecast, 2020-2028
4.5.1 Communicable Diseases Treatment Market Size and Y-o-Y Growth
4.5.2 Communicable Diseases Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 HIV
5.2.2 Influenza
5.2.3 TB
5.2.4 Malaria
5.2.5 Hepatitis
5.2.6 HPV
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Communicable Diseases Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Communicable Diseases Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 HIV
9.6.2 Influenza
9.6.3 TB
9.6.4 Malaria
9.6.5 Hepatitis
9.6.6 HPV
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 HIV
10.6.2 Influenza
10.6.3 TB
10.6.4 Malaria
10.6.5 Hepatitis
10.6.6 HPV
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 HIV
11.6.2 Influenza
11.6.3 TB
11.6.4 Malaria
11.6.5 Hepatitis
11.6.6 HPV
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 HIV
12.6.2 Influenza
12.6.3 TB
12.6.4 Malaria
12.6.5 Hepatitis
12.6.6 HPV
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 HIV
13.6.2 Influenza
13.6.3 TB
13.6.4 Malaria
13.6.5 Hepatitis
13.6.6 HPV
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Communicable Diseases Treatment Market: Competitive Dashboard
14.2 Global Communicable Diseases Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Gilead
14.3.3 GSK
14.3.4 Janssen Pharmaceutical
14.3.5 Roche
14.3.6 BioCryst Pharmaceuticals
14.3.7 Merck
14.3.8 Boehringer Ingelheim
